Login to Your Account

Shares Fall After Hours

FDA Panel Rejects Arena's Weight Loss Drug Lorcaserin

By Donna Young

Friday, September 17, 2010
ADELPHI, Md. – An FDA panel Thursday said the potential risks of tumors, psychiatric effects and heart problems outweighed any benefits of weight loss with Arena Pharmaceuticals Inc.'s Lorquess (lorcaserin). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription